Germany’s Merck KGaA has presented detailed results from cohort B of the global Phase II WILLOW study of enpatoran, an ...

German science and technology firm Merck KGaA (MRK: DE) has moved a step closer to introducing a new therapy for tenosynovial ...

It remains unclear when production will start. More retail could fill site along K-10 near Panasonic Merck plans $895M ...

MRK), and Kansas Governor Laura Kelly jointly announced today the $895 million expansion of Merck Animal Health’s manufacturing facility in De Soto, Kansas.

Plant Services Smart Minute is a content based enewsletter where readers will find exclusive content, relevant industry news, useful case studies, access to Plant Services on-demand webcasts, and ...

Triple-negative breast cancer (TNBC) - closeup view 3d illustration] Nemes Laszlo/iStock via Gilead Sciences (NASDAQ:GILD [ announced Saturday that its antibody-drug conjugate Trodelvy, in ...

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's ...

New findings suggest that a PSA level of 0.2 ng/mL or greater can predict a poor prognosis and indicate a possible need for ...

Navigating a complex drug development landscape, sponsors must rethink their approach to risk in study design and execution.

(MRK) announced that KEYTRUDA (pembrolizumab) plus Trodelvy (sacituzumab govitecan-hziy) reduced the risk of disease progression or death by 35% compared to KEYTRUDA plus chemotherapy for the ...

MoonLake Immunotherapeutics' Sonelokimab's Phase 3 trials, PsA market growth, and Merck's $3B bid showcase potential. Read my ...

Colorectal cancer highlights from ASCO 2025 include findings from the BREAKWATER, ATOMIC, DYNAMIC-III, and TRIPLETE trials.